This is a double-blind, placebo-controlled study during which patients will receive ricolinostat or placebo.~Prior to randomization, patients will participate in the Screening and Baseline assessment period to ensure that they meet study inclusion/exclusion criteria.~Following the Screening and Baseline assessment period, patients who meet entry criteria will be randomized in a 2:1 ratio to receive either ricolinostat or placebo.
This is a double-blind, placebo-controlled study during which patients will receive ricolinostat or placebo.